BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Not Applicable

• Conditions: -M080 Juvenile rheumatoid arthritis; Juvenile rheumatoid arthritis; M080

• Registration Number: PER-012-04
• Lead Sponsor: BRISTOL MYERS SQUIBB COMPANY,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-05-17
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

Diagnosis of juvenile rheumatoid arthritis or juvenile idiopathic arthritis;
Current active arthritis;
Failed treatment with at least one disease modifying antirheumatic drug (DMARD);
Subjects should discontinue the use of any DMARD other than methotrexate before the first dose of study medication

Exclusion Criteria

Presence of infection or a history of frequent acute or chronic infections;
Joint replacement surgery required during the study or history of surgery in more than 5 joints;
Live vaccines within 3 months of the first dose of the study medication;
Severe unresolved bacterial infection or chronic bacterial infection;
Subjects who currently have intermittent fever due to ARJ / JIA, rheumatoid exanthema, hepato-splenomegaly, pleuritis, pericarditis or macrophage activation syndrome.

Study & Design

• Study Type: Interventional
• Study Design: Not specified